Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]


On page 193 note that the paragraph beginning “Pacritinib (SB1518; Cell Technology, Inc, Mountain View, CA, USA) is a JAK2 and FLT3 inhibitor currently being evaluated at a dose of 400 mg daily in a Phase II study (N=34) that included patients with low platelet counts (<50 × 10^9/L).” should have been “Pacritinib (SB1518; Cell Therapeutics, Inc, Seattle, WA, USA) is a JAK2 and FLT3 inhibitor which was evaluated at a dose of 400 mg daily in a Phase II study (N=34) that included patients with low platelet counts (<50 × 10^9/L).”

On page 193 in the same paragraph note that “Post-Essential Thrombocythemia Myelofibrosis: PERSIST)” should have been “Post-Essential Thrombocythemia Myelofibrosis-1: PERSIST-1).”